TC Biopharm (Holdings) Plc TCBP
Set alert
0.50 USD 0.00 0.00%
At close · Mar 21
0.50 Day range 1.51
0.436 52-week range 41.50
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 1.51
- Prev close
- 0.50
- Mkt cap
- 5.22M
- Vol
- 5.90M
- Avg vol
- 1.69M
- EPS
- -294.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.50
- High
- 1.51
- Forward P/E
- -0.14
- Beta
- 0.25
- Short ratio
- 0.02
- Inst. own
- 7.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 6, 2024
- 50-d avg
- 1.47
- 200-d avg
- 7.74
- 1y target
- 3.00
Key statistics
- Market cap
- 5.22M
- Enterprise value
- 59.49M
- Trailing P/E
- 0.00
- Forward P/E
- -0.14
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.02
- EPS (TTM)
- -294.87
- Beta
- 0.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.85M
- Total cash
- 980.96K
- Total debt
- 1.73M
- Return on equity
- -1217.48%
- Shares outstanding
- 8.21M
- Short % of float
- 6.99%
- 50-day average
- 1.47
- 200-day average
- 7.74
Analyst view
Consensus: none
Price target (mean) 3.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
May 6, 2024
Expected May 6, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TCBP Revenue — quarterly 0
TCBP Net income — quarterly -1.99M
TCBP EPS — quarterly 96.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2024 | Dec 1, 2023 | -14.00 | — | — | — |
| May 12, 2023 | Dec 1, 2022 | -5.58 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- tcbiopharm.com
News
- TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
- TCBP Announces Transition from Nasdaq to OTC Markets
- TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
- TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
- TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
- TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
- TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
- TCBP to Implement ADS Ratio Change
- TCBP Announces H5N1 Proof of Concept Studies Intention
- TCBP to Present at Sequire Investor Summit 2025
Your note
Sign in to keep a note on TCBP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FNY Investment Advisers, LLC | 0.10% | 8,200 | 5.21K | Sep 29, 2024 |
| SignatureFD, LLC | 0.01% | 492 | 312 | Sep 29, 2024 |
| New England Capital Financial Advisors LLC | 0.00% | 201 | 127 | Sep 29, 2024 |
| Harbour Investments, Inc. | 0.00% | 236 | 150 | Sep 29, 2024 |
| Sanctuary Wealth Management, L.L.C. | 0.00% | 12 | 7 | Sep 29, 2024 |
| Rhumbline Advisers | 0.00% | 83 | 52 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust For Professional Managers-PMC Diversified Equity Fund | 0.05% | 19,068 | 12.13K | Aug 30, 2022 |